MetaCap

iBio Inc. (IBIO)

NASDAQ: IBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.8001-0.0009 (-0.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IBIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$56.37M
EPS (TTM)
-$0.27
52-week range
0.68 – 3.82
Day range
0.7626 – 0.8266
Volume / Avg
3.36M / 678.91K
Beta
—

52-week range

$0.68$3.82

IBIO stock today

iBio (IBIO) closed at $0.8001 on Nov 20, down 0.11% (-$0.0009), versus the S&P 500's 3.70% decline. Volume was 5.0x the average at 3.36M shares, a sign of unusually heavy trading. Shares are 79.1% below their 52-week high of $3.82, set on Dec 10, 2025 and 17.7% above the 52-week low of $0.68, near the bottom of the past year's range.

IBIO is down 58.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.8%. iBio has posted a net loss over the last twelve months (EPS of -$0.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About iBio

Company profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Headquarters
San Diego, CA
Employees
23

Financial highlights

Full financials

In fiscal 2026, iBio generated $100,000 in revenue, down 75.0% from fiscal 2025, its first annual decline since 2023. iBio reported a net loss of $33.0 million, compared with a loss of $18.4 million a year earlier. Operating margin was -35141.0%.

iBio annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$100.00K$400.00K$225.00K$0$1.88M
Growth-75.00%+77.78%—-100.00%-20.54%
Net income$-33.04M$-18.38M$-24.91M$-65.01M$-50.30M
EPS (diluted)$-0.32$-1.75$-6.50$-106.19$-5.78

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$5.69+611.16%

  • Strong buy 1
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.20High $7.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.05 vs $-0.06
Surprise
+16.67%

IBIO news

All IBIO news

iBio peers

Health Care sector
IBIO peer companies
CompanyPrice% ChgMarket capCompare
KZIAKazia Therapeutics Limited ADR4.92-8.38%$56.22Mvs IBIO
TENXTenax Therapeutics Inc.1.25-10.07%$56.92Mvs IBIO
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs IBIO
BOLDBoundless Bio Inc.2.32-2.52%$54.78Mvs IBIO
RANIRani Therapeutics Holdings Inc. Class A0.5111-11.97%$59.03Mvs IBIO
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs IBIO
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs IBIO
XBITXBiotech Inc.1.73+2.98%$52.74Mvs IBIO

Indexes, lists and sector

iBio stock FAQ

What is iBio's stock price today?

IBIO last traded at $0.8001 as of Nov 20, 4:00 PM EST, down 0.11% on the day. Prices are delayed at least 15 minutes.

Does iBio pay a dividend?

No. iBio does not currently pay a regular cash dividend.

Who is iBio's CEO?

Dr. Martin B. Brenner D.V.M., Ph.D. is the chief executive officer of iBio Inc., which has about 23 employees.

Has IBIO ever split its stock?

Yes. The most recent IBIO stock split was a 1-for-20 split on Nov 29, 2023, one of 3 splits on record.

What is the IBIO 52-week high?

The 52-week high for IBIO is $3.82 and the 52-week low is $0.68. The stock is currently 79.1% below its high.

Compare IBIO